ClinicalTrials.gg
CompletedNCT02972632Updated Jul 11, 2019Results posted

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

A Phase 4 interventional study of Vortioxetine in Major Depressive Disorder, sponsored by Takeda. Completed at 25 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-11.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
39th of 54
123 · median 413
Started
2016
with 8 others
Phase 4
13 of 54
none open now
Registered
40th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 39th largest by enrollment, is one of 9 that started in 2016, is one of 13 in phase 4, and was the 40th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).

Read the detailed description

The drug being tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in people who have major depressive disorder. This study will look at effectiveness of treatment with vortioxetine in participant's goal achievement for the treatment of major depressive disorder.

The study enrolled 123 patients. Participants will receive:

  • Vortioxetine 10 to 20 mg

All participants will be asked to take one tablet at the same time each day throughout the study. The participants will receive a starting dose of 10 mg. The dose may be up-titrated to 20 mg. The dose may then be decreased by 5 mg based on participant's response and tolerability to higher dose as judged by the Investigator.

This multi-center trial will be conducted in Unites States. The overall time to participate in this study is 19 weeks. Participants will make multiple visits to the clinic and will be contacted by telephone for 4 weeks after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is suffering from Major Depressive Disorder (MDD) as the primary psychiatric diagnosis.
  2. Has been or is currently being treated with an approved antidepressant (monotherapy) for 6 weeks or longer at an adequate therapeutic dose. Participants currently on an antidepressant at Screening will be discontinued in a manner that is consistent with labeling recommendations and conventional medical practice.
  3. The antidepressant treatment must be on-going at time of Screening or have been discontinued within the 6 weeks prior to Screening.
  4. Is considered appropriate for a change in antidepressant medication based on Investigator judgment in collaboration with the participant.
  5. Has scores on Patient Health Questionnaire (PHQ-9) ≥5 and Clinical Global Impression Scale Severity (CGI-S ≥4).

Exclusion criteria

Exclusion Criteria:

  1. Has discontinued prior antidepressant treatment greater than 6 weeks from Screening.
  2. Is considered to be at imminent risk for hospitalization due to severe depression in the opinion of the investigator. Recent hospitalization due to MDD within 3 months prior to Screening is exclusionary also.
  3. Has a significant risk of suicide according to the Investigator's clinical judgment or has made an actual suicide attempt in the previous 6 months prior to Screening or scores "yes" on items 4 or 5 in the past 6 months on the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C-SSRS).
  4. Is considered to be treatment resistant, defined as participants with MDD who have not responded to 2 or more separate different antidepressant monotherapy trials of adequate dose and duration (6 weeks or longer) in their current episode. History of only responding to combination or augmentation therapy in previous major depressive episode (MDEs) is also considered evidence of treatment resistant depression.
  5. Has 1 or more of the following:

    1. Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in (DSM-5) as determined by the investigator.
    2. Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine). The participants must have a negative urine drug screen (UDS) at Screening and Baseline, this includes benzodiazepines and opiates (including oxycodone) for which there is no prescription.
    3. Presence or history of a neurological disorder (including epilepsy) as determined by the investigator.
    4. Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
  6. Has a known history of acute narrow-angle glaucoma or is at risk of acute narrow-angle glaucoma.
  7. Has a known unstable thyroid disorder or a thyroid-stimulating hormone value outside the normal range based on medical history that is deemed clinically significant by the investigator.
  8. Has active or a known history of virus.
  9. Has a known history of infection.
  10. Has a history of gastric bypass.
  11. Has previously or is currently participating in this study or another vortioxetine or LuAA21004 study.
  12. Is receiving or who have started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plan to initiate such therapy during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10-20 mg

    Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.

    Drug: Vortioxetine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of ≥50 at Week 12

    GAS is a tool to measure progress each participant has towards achieving their individualized goals. The standardized scoring was applied for statistical analysis. A semi-structured interview was conducted with each participant to conduct goal-setting at the outset of study. Another evaluation took place at end of study (EOS) visit to determine the level of progress at that time. The score for each goal ranged from -2 (much worse) to +2 (much better). GAS yielded a norm-based score standardized to a mean of 50 with a standard deviation (SD) of 10. Higher score indicates composite of 3 goals (50 or above) as response.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Total Goal Attainment Scale Score at Weeks 6 and 12

    GAS is a tool to measure progress each participant has towards achieving their individualized goals. The standardized scoring was applied for statistical analysis. A semi-structured interview was conducted with each participant to conduct goal-setting at outset of study. Another evaluation took place at EOS visit to determine level of progress at that time. The score for each goal ranged from -2 (much worse) to +2 (much better). GAS yielded a norm-based score standardized to a mean of 50 with SD of 10. The total score ranges between 22.6 and 77.4. A positive change from baseline in the composite of 3 goals (50 or above) indicates response.

    Time frame: Baseline and Weeks 6 and 12

  2. Change From Baseline in Patient Health Questionnaire (PHQ-9) Score at Weeks 6 and 12

    PHQ-9 is a well-established participant reported outcome tool for assessment of change in depressive symptoms and is a sensitive measure of depression severity. The PHQ-9 consists of a 9-item scale originally developed for primary care settings, with 1 item corresponding to each of the 9 made symptom criteria for depression in diagnostic and statistical manual of mental disorders (DSM), asking if they have bothered the participant over the last 2 weeks. Each question is rated on a scale from 0 (not at all) to 3 (nearly every day). If any problems are answered 1 or higher, a final question on how difficult those problems made it to do work, take care of things at home, or get along with other people is completed, rated from not difficult at all to extremely difficult. The 9 questions are summed to a total score ranging from 0 to 27 with higher scores reflecting greater severity. A positive change from baseline indicates severe condition.

    Time frame: Baseline and Weeks 6 and 12

  3. Change From Baseline in Perceived Deficits Questionnaire-Depression (PDQ-D) at Weeks 6 and 12

    The PDQ-D is a 20-item, patient-reported questionnaire with a 7-day recall period. Scores for four subscales. All 20 items use the same 5-point ordinal categorical response scale to reflect the frequency of experiencing a specific cognitive problem in the past 7 days. Scores for each of the four measured subscales are calculated by assigning a value of 0 ("never in the past 7 days"), 1 ("rarely - once or twice"), 2 ("sometimes - 3-5 times"), 3 ("often - about once a day"), or 4 ("very often - more than once a day") to each item, then summing the five items of that subscale, to produce a score ranging from 0 to 20. A total global score for overall cognitive dysfunction (range 0-80) is calculated by summing the four subscale scores. Higher scores for each subscale and for the total score indicate greater perceived cognitive dysfunction. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 6 and 12

  4. Change From Baseline in Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) Total Score at Week 12

    Q-LES-Q is a scale designed to allow researchers to assess the degree of a participant's quality of life in various areas of daily living. There is not a "Total Score" per se for the Q-LES-Q. The scale is divided into domains. Ninety-one of the 93 items are assembled into 8 categories: physical health/activities, feelings, work, household duties, school/course work, leisure time activities, social relations, and general activities. Items are scored on a 5 point scale, from 1 (not at all or never) to 5 (frequently or all the time), to indicate the degree of enjoyment or satisfaction experienced by domain. Raw summary scores are expressed as a percentage of the maximum possible score within a given domain to facilitate comparisons across areas of functioning. The total score is based on the Overall Life Satisfaction question in General Activities and ranges from 1 to 5. A positive change from baseline indicates greater enjoyment/satisfaction.

    Time frame: Baseline and Week 12

  5. Change From Baseline in 5-Item World Health Organization Well-being Index (WHO-5) Score at Week 12

    WHO-5 is a short, self-administered questionnaire covering 5 positively worded items, related to positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interests (being interested in things). Each of the five items is rated from 0 (= not present) to 5 (= constantly present). Scores are summated, with raw score ranging from 0 to 25, with higher score meaning better well-being. A positive change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  6. Change From Baseline in Clinical Global Impression Scale Severity (CGI-S) at Week 12

    CGI-S is a clinician rated scale designed to assess global severity of illness and change in the clinical condition over time. The CGI-S provides the clinician's impression of the participant's state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's mental illness on a 7-point scale ranging from 1 (normal-not at all ill) to 7 (among the most extremely ill participants). Higher scores indicate greater severity of illness. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  7. Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 12

    CGI-I assesses the participant's improvement (or worsening). The clinician assessed participant's condition on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicated greater severity of illness.

    Time frame: Week 12

07

Results

Posted Jul 11, 2019

Participant flow

Participants took part in the study at 23 investigative sites in United States from 22 December 2016 to 06 February 2018.

Participant flow — Overall Study
MilestoneVortioxetine
Started123
Safety analysis set122
Completed106
Not completed17
Withdrew: Pretreatment event/adverse event3
Withdrew: Lost to follow-up4
Withdrew: Voluntary withdrawal10

Outcome measures

PrimaryPercentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of ≥50 at Week 12

GAS is a tool to measure progress each participant has towards achieving their individualized goals. The standardized scoring was applied for statistical analysis. A semi-structured interview was conducted with each participant to conduct goal-setting at the outset of study. Another evaluation took place at end of study (EOS) visit to determine the level of progress at that time. The score for each goal ranged from -2 (much worse) to +2 (much better). GAS yielded a norm-based score standardized to a mean of 50 with a standard deviation (SD) of 10. Higher score indicates composite of 3 goals (50 or above) as response.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of ≥50 at Week 12
percentage of participantsVortioxetine
Percentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of ≥50 at Week 1257.8 (48.5 to 67.1)
SecondaryChange From Baseline in Total Goal Attainment Scale Score at Weeks 6 and 12

GAS is a tool to measure progress each participant has towards achieving their individualized goals. The standardized scoring was applied for statistical analysis. A semi-structured interview was conducted with each participant to conduct goal-setting at outset of study. Another evaluation took place at EOS visit to determine level of progress at that time. The score for each goal ranged from -2 (much worse) to +2 (much better). GAS yielded a norm-based score standardized to a mean of 50 with SD of 10. The total score ranges between 22.6 and 77.4. A positive change from baseline in the composite of 3 goals (50 or above) indicates response.

Time frame:
Baseline and Weeks 6 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Total Goal Attainment Scale Score at Weeks 6 and 12
score on a scaleVortioxetine
Baseline23.57 ± 0.073
Change at Week 618.21 ± 11.470
Change at Week 1226.94 ± 13.582
Statistical analysis
  • Vortioxetine · t-test, 2 sided · p = <0.001
  • Vortioxetine · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Patient Health Questionnaire (PHQ-9) Score at Weeks 6 and 12

PHQ-9 is a well-established participant reported outcome tool for assessment of change in depressive symptoms and is a sensitive measure of depression severity. The PHQ-9 consists of a 9-item scale originally developed for primary care settings, with 1 item corresponding to each of the 9 made symptom criteria for depression in diagnostic and statistical manual of mental disorders (DSM), asking if they have bothered the participant over the last 2 weeks. Each question is rated on a scale from 0 (not at all) to 3 (nearly every day). If any problems are answered 1 or higher, a final question on how difficult those problems made it to do work, take care of things at home, or get along with other people is completed, rated from not difficult at all to extremely difficult. The 9 questions are summed to a total score ranging from 0 to 27 with higher scores reflecting greater severity. A positive change from baseline indicates severe condition.

Time frame:
Baseline and Weeks 6 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Patient Health Questionnaire (PHQ-9) Score at Weeks 6 and 12
score on a scaleVortioxetine
Baseline15.7 ± 4.79
Change at Week 6-6.5 ± 6.15
Change at Week 12-8.4 ± 6.22
Statistical analysis
  • Vortioxetine · t-test, 2 sided · p = <0.001
  • Vortioxetine · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Perceived Deficits Questionnaire-Depression (PDQ-D) at Weeks 6 and 12

The PDQ-D is a 20-item, patient-reported questionnaire with a 7-day recall period. Scores for four subscales. All 20 items use the same 5-point ordinal categorical response scale to reflect the frequency of experiencing a specific cognitive problem in the past 7 days. Scores for each of the four measured subscales are calculated by assigning a value of 0 ("never in the past 7 days"), 1 ("rarely - once or twice"), 2 ("sometimes - 3-5 times"), 3 ("often - about once a day"), or 4 ("very often - more than once a day") to each item, then summing the five items of that subscale, to produce a score ranging from 0 to 20. A total global score for overall cognitive dysfunction (range 0-80) is calculated by summing the four subscale scores. Higher scores for each subscale and for the total score indicate greater perceived cognitive dysfunction. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 6 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Perceived Deficits Questionnaire-Depression (PDQ-D) at Weeks 6 and 12
score on a scaleVortioxetine
Baseline40.5 ± 14.87
Change at Week 6-14.8 ± 13.70
Change at Week 12-18.0 ± 16.92
Statistical analysis
  • Vortioxetine · t-test, 2 sided · p = <0.001
  • Vortioxetine · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) Total Score at Week 12

Q-LES-Q is a scale designed to allow researchers to assess the degree of a participant's quality of life in various areas of daily living. There is not a "Total Score" per se for the Q-LES-Q. The scale is divided into domains. Ninety-one of the 93 items are assembled into 8 categories: physical health/activities, feelings, work, household duties, school/course work, leisure time activities, social relations, and general activities. Items are scored on a 5 point scale, from 1 (not at all or never) to 5 (frequently or all the time), to indicate the degree of enjoyment or satisfaction experienced by domain. Raw summary scores are expressed as a percentage of the maximum possible score within a given domain to facilitate comparisons across areas of functioning. The total score is based on the Overall Life Satisfaction question in General Activities and ranges from 1 to 5. A positive change from baseline indicates greater enjoyment/satisfaction.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) Total Score at Week 12
score on a scaleVortioxetine
Baseline2.487 ± 0.8822
Change at Week 121.128 ± 1.1871
Statistical analysis
  • Vortioxetine · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in 5-Item World Health Organization Well-being Index (WHO-5) Score at Week 12

WHO-5 is a short, self-administered questionnaire covering 5 positively worded items, related to positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interests (being interested in things). Each of the five items is rated from 0 (= not present) to 5 (= constantly present). Scores are summated, with raw score ranging from 0 to 25, with higher score meaning better well-being. A positive change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in 5-Item World Health Organization Well-being Index (WHO-5) Score at Week 12
score on a scaleVortioxetine
Baseline5.6 ± 3.48
Change at Week 127.2 ± 6.59
Statistical analysis
  • Vortioxetine · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Clinical Global Impression Scale Severity (CGI-S) at Week 12

CGI-S is a clinician rated scale designed to assess global severity of illness and change in the clinical condition over time. The CGI-S provides the clinician's impression of the participant's state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's mental illness on a 7-point scale ranging from 1 (normal-not at all ill) to 7 (among the most extremely ill participants). Higher scores indicate greater severity of illness. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression Scale Severity (CGI-S) at Week 12
score on a scaleVortioxetine
Baseline4.4 ± 0.50
Change at Week 12-1.6 ± 1.10
Statistical analysis
  • Vortioxetine · t-test, 2 sided · p = <0.001
SecondaryClinical Global Impression Scale-Improvement (CGI-I) Score at Week 12

CGI-I assesses the participant's improvement (or worsening). The clinician assessed participant's condition on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicated greater severity of illness.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 12
score on a scaleVortioxetine
Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 122.2 ± 1.05

Adverse events

Collected over Baseline up to Day 113. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine0/122 (0%)1/122 (0.8%)46/122 (37.7%)
Most frequent serious events
Most frequent serious events
EventVortioxetine
DepressionPsychiatric disorders1/122
Suicidal IdeationPsychiatric disorders1/122
Most frequent other events
Most frequent other events
EventVortioxetine
NauseaGastrointestinal disorders26/122
HeadacheNervous system disorders11/122
AnxietyPsychiatric disorders8/122
ConstipationGastrointestinal disorders7/122
DiarrhoeaGastrointestinal disorders7/122

Baseline characteristics

Safety analysis set included all participants who were enrolled and received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Vortioxetine
Mean45.3 ± 12.22
Age, Customized
Age, Customized(Participants)Vortioxetine
<= 55 Years95
> 55 Years27
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine
Female101
Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vortioxetine
Hispanic or Latino28
Not Hispanic or Latino94
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vortioxetine
Asian5
Black or African American28
Native Hawaiian or Other Pacific Islander1
White83
Multiracial3
Unknown2
Region of Enrollment
Region of Enrollment(Participants)Vortioxetine
United States122
Height
Height(cm)Vortioxetine
Mean164.5 ± 10.43
Weight
Weight(kg)Vortioxetine
Mean91.59 ± 23.118

2 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Pacific Research Partners
    Oakland, California 94607, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • University Medical Group
    Upland, California 91207, United States
  • MCB Clinical Research Centers, LLC
    Colorado Springs, Colorado 80910, United States
  • Suncoast Clinical Research Inc.
    New Port Richey, Florida 34652, United States
  • Behavioral Clinical Research , Inc
    North Miami, Florida 33162, United States
  • Compass Research Main
    Orlando, Florida 32806, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • Deaconess Clinic
    Evansville, Indiana 47713-1227, United States
  • Novex Clinical Research, LLC
    New Bedford, Massachusetts 2740, United States
  • Coastal Research Associates, Inc.
    South Weymouth, Massachusetts 2190, United States
  • University of Michigan, Ann Arbor
    Ann Arbor, Michigan 48109, United States
  • Columbia University Medical Center
    New York, New York 10023, United States
  • Dayton Clinical Research
    Dayton, Ohio 45406, United States
  • Green & Seidner Family Practice Associates
    Lansdale, Pennsylvania 19446, United States
  • Relaro Medical Trials
    Dallas, Texas 75243, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Radiant Research, Inc.
    San Antonio, Texas 78229, United States
  • Family Psychiatry of The Woodlands
    The Woodlands, Texas 77381, United States
09

References and documents

Publications

  • McCue M, Sarkey S, Eramo A, Francois C, Parikh SV. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study. BMC Psychiatry. 2021 Dec 11;21(1):622. doi: 10.1186/s12888-021-03608-1. Erratum In: BMC Psychiatry. 2022 Mar 7;22(1):170. doi: 10.1186/s12888-022-03798-2. BMC Psychiatry. 2022 Jun 8;22(1):388. doi: 10.1186/s12888-022-03975-3. PubMed 34895181 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Feb 2018, 13 months.

Results were first posted in Jul 2019, 1 year 5 months after primary completion.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Nov 23, 2016
StartActual
Dec 22, 2016
Primary completionActual
Feb 6, 2018
CompletionActual
Feb 6, 2018
Results first posted
Jul 11, 2019
Last update
Jul 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02972632
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 23, 2016
Start date
Dec 22, 2016
Primary completion
Feb 6, 2018
Completion
Feb 6, 2018
Results posted
Jul 11, 2019
Last update
Jul 11, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion